Literature DB >> 11040111

Enhanced expression and activity of xanthine oxidoreductase in the failing heart.

J W de Jong1, R G Schoemaker, R de Jonge, P Bernocchi, E Keijzer, R Harrison, H S Sharma, C Ceconi.   

Abstract

The molecular basis for heart failure is unknown, but oxidative stress is associated with the pathogenesis of the disease. We tested the hypothesis that the activity of xanthine oxidoreductase (XOR), a free-radical generating enzyme, increases in hypertrophied and failing heart. We studied XOR in two rat models: (1) The monocrotaline-induced right ventricular hypertrophy and failure model; (2) coronary artery ligation induced heart failure, with left ventricular failure and compensatory right ventricular hypertrophy at different stages at 3 and 8 weeks post-infarction, respectively. XOR activity was measured at 30 degrees C and the reaction products were analysed by HPLC. In both models XOR activity in hypertrophic and control ventricles was similar. In the monocrotaline model, the hearts showed enhanced XOR activity in the failing right ventricle (65+/-5 mU/g w/w), as compared to that in the unaffected left ventricle (47+/-3 mU/g P<0.05, n=6-7). In the coronary ligation model, XOR activities did not differ at 3 and 8 weeks. In the infarcted left ventricle, XOR activity increased from 29.4+/-1.4 mU/g (n=6) in sham-operated rats, to 48+/-3 and 80+/-6 mU/g (n=8 P<0.05 v sham) in the viable and infarcted parts of failing rat hearts, respectively. With affinity-purified polyclonal antibody, XOR was localized in CD68+ inflammatory cells of which the number increased more in the failing than in sham-operated hearts. Our results show that the expression of functional XOR is elevated in failing but not in hypertrophic ventricles, suggesting its potential role in the transition from cardiac hypertrophy into failure. Copyright 2000 Academic Press.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11040111     DOI: 10.1006/jmcc.2000.1240

Source DB:  PubMed          Journal:  J Mol Cell Cardiol        ISSN: 0022-2828            Impact factor:   5.000


  26 in total

Review 1.  Are either or both hyperuricemia and xanthine oxidase directly toxic to the vasculature? A critical appraisal.

Authors:  Tuhina Neogi; Jacob George; Sushma Rekhraj; Allan D Struthers; Hyon Choi; Robert A Terkeltaub
Journal:  Arthritis Rheum       Date:  2012-02

Review 2.  Genomics and the pathophysiology of heart failure.

Authors:  J J Hwang; V J Dzau; C C Liew
Journal:  Curr Cardiol Rep       Date:  2001-05       Impact factor: 2.931

Review 3.  Pharmacologic strategies to target oxidative stress in heart failure.

Authors:  Zain Ahmed; W H Wilson Tang
Journal:  Curr Heart Fail Rep       Date:  2012-03

Review 4.  Therapeutic effects of xanthine oxidase inhibitors: renaissance half a century after the discovery of allopurinol.

Authors:  Pál Pacher; Alex Nivorozhkin; Csaba Szabó
Journal:  Pharmacol Rev       Date:  2006-03       Impact factor: 25.468

5.  Hyperuricaemia, chronic kidney disease, and outcomes in heart failure: potential mechanistic insights from epidemiological data.

Authors:  Gerasimos S Filippatos; Mustafa I Ahmed; James D Gladden; Marjan Mujib; Inmaculada B Aban; Thomas E Love; Paul W Sanders; Bertram Pitt; Stefan D Anker; Ali Ahmed
Journal:  Eur Heart J       Date:  2011-01-03       Impact factor: 29.983

6.  Oxidant stress from nitric oxide synthase-3 uncoupling stimulates cardiac pathologic remodeling from chronic pressure load.

Authors:  Eiki Takimoto; Hunter C Champion; Manxiang Li; Shuxun Ren; E Rene Rodriguez; Barbara Tavazzi; Giuseppe Lazzarino; Nazareno Paolocci; Kathleen L Gabrielson; Yibin Wang; David A Kass
Journal:  J Clin Invest       Date:  2005-04-14       Impact factor: 14.808

7.  Neuronal nitric oxide synthase negatively regulates xanthine oxidoreductase inhibition of cardiac excitation-contraction coupling.

Authors:  Shakil A Khan; Kwangho Lee; Khalid M Minhas; Daniel R Gonzalez; Shubha V Y Raju; Ankit D Tejani; Dechun Li; Dan E Berkowitz; Joshua M Hare
Journal:  Proc Natl Acad Sci U S A       Date:  2004-10-14       Impact factor: 11.205

8.  Targeted antioxidant treatment decreases cardiac alternans associated with chronic myocardial infarction.

Authors:  Bradley N Plummer; Haiyan Liu; Xiaoping Wan; Isabelle Deschênes; Kenneth R Laurita
Journal:  Circ Arrhythm Electrophysiol       Date:  2014-12-09

Review 9.  Redox signaling in cardiovascular health and disease.

Authors:  Nageswara R Madamanchi; Marschall S Runge
Journal:  Free Radic Biol Med       Date:  2013-04-11       Impact factor: 7.376

10.  Non-purine selective xanthine oxidase inhibitor ameliorates glomerular endothelial injury in InsAkita diabetic mice.

Authors:  Seiji Itano; Hiroyuki Kadoya; Minoru Satoh; Takashi Nakamura; Takayo Murase; Tamaki Sasaki; Yashpal S Kanwar; Naoki Kashihara
Journal:  Am J Physiol Renal Physiol       Date:  2020-09-21
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.